Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

Diabetes Therapy

Volumn 5, Issue 2, 2014, Pages 499-520

  Divino, Victoria ^a   DeKoven, Mitch ^a   Hallinan, Shawn ^a   Varol, Nebibe ^b   Wirta, Sara Bruce ^a   Lee, Won Chan ^a   Reaney, Matthew ^b  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Databases; Diabetes mellitus; Exenatide BID; Exenatide QW; Glucagon like peptide 1; Liraglutide; Retrospective studies; Treatment outcome; Type 2 drug therapy

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE;

ADULT; AGED; ARTICLE; BELGIUM; BODY MASS; COMORBIDITY; DEPRESSION; FEMALE; FOLLOW UP; FRANCE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRESCRIPTION; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84919666384     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0087-6     Document Type: Article

References (16)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels: International Diabetes Federation; 2013. http://www.idf.org/diabetesatlas. Accessed February 18, 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
3. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370:794–7.
4. Byetta: EPAR—European Medicines Agency—Europa, European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/000698/WC500051845.pdf (2011). Accessed March 28, 2013.
5. Victoza: EPAR—Product Information—European Medicines Agency. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/001026/WC500050017.pdf (2014). Accessed October 21, 2014.
6. European Medicines Agency: Assessment report for Victoza. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf. Accessed September 16, 2013.
7. Type 2 Diabetes—newer agents (partial update of CG66) (CG87): NICE clinical guidelines. http://publications.nice.org.uk/type-2-diabetes-cg87 (2009). Accessed February 20, 2013.
8. Bydureon: EPAR—Product information—European Medicines Agency. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf (2011). Accessed March 12, 2013.
9. http://medicijnbalans.nl/medicijngroepen/diabetes-type-2/middel/99 (2014). Accessed October 21, 2014.
10. National Guidelines for Diabetes Care—summary. Socialstyrelsen. http://www.socialstyrelsen.se/nationalguidelines/nationalguidelinesfordiabetescare (2010). Accessed February 12, 2014.
11. Scheen AJ, Van Gaal LF. Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes. Rev Med Liege. 2010;65:464–70.
12. McDonell A, Zammit DC, Haslam T, et al. PDB35 estimating the real life daily usage and daily cost of GLP-1 receptor agonists in the UK setting. Value Health. 2011;14:A477–8.
13. Miller LA, Burudpakdee C, Zagar A, et al. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ. 2012;15:746–57.
14. Fuchs S, Kostev L, Seitz L, Wohlleben M. Ermittlung der tatsächlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten. Diabetologie und Stoffwechsel. 2011;6:P234.
15. Buitenhuis R. Impact of a restrictive reimbursement policy on access, costs and quality and safety of treatment: Analysis of a Dutch reimbursement case regarding GLP-1 therapy. Masters thesis, Erasmus University, Rotterdam. http://thesis.eur.nl/pub/12738/Buitenhuis%20R%20351371.pdf (2012). Accessed September 22, 2014.
16. Decision Resources: European physician and payer forum. DPP-IV inhibitors and GLP-1 analogues for Type 2 diabetes—how are physician and payer perspectives shaping the European markets? http://decisionresources.com/Products-and-Services/Report?r=pforeu0611 (2011). Accessed September 23, 2014.